The trajectory of Viagra presents a complex picture for those considering investment. While the initial release generated substantial returns, the end of its exclusive rights opened the avenue to generic competitors, dramatically eroding sales. This creates a unique challenge for pharmaceutical companies relying on comparable blockbuster offerings,

The history of Viagra, and its creator copyright, presents a complex case study for investors. Originally a blockbuster drug, generating billions in income, its exclusivity period created a flood of lower-priced alternatives , significantly eroding its dominance. While certain firms may try to capitalize on male sexual dysfunction, the current land